World Changers (3.14.2025)January 1, 1970Dr Jack Cush and his podcast friends are out to change the world. Here…View Resource Emapalumab for the treatment of macrophage activation syndromeJanuary 1, 1970Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a…View Resource Rheumatic Associated Macrophage Activation SyndromeJanuary 1, 1970Macrophage Activation Syndrome (MAS) is a hyperinflammatory condition that has a significant mortality risk and…View Resource Still’s Disease FAQsJanuary 1, 1970What is the classic ‘triad’ of Still’s disease? Does it affect males and females…View Resource ACR 2022 Appraisal, Praise & Critique (11.18.2022)January 1, 1970It was great to be back at an ACR annual meeting, this one in…View Resource Here at Last: Treatment Options for VEXASJanuary 1, 1970We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…View Resource ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory SyndromesJanuary 1, 1970Editor’s note: This article originally appeared March 12, 2024, and is being shared again…View Resource ERA, APPs, & Alpha GAL (3.21.2025)January 1, 1970Dr. Jack Cush reviews the news and journal reports from this past week on…View Resource ←123456789…1011121314
Emapalumab for the treatment of macrophage activation syndromeJanuary 1, 1970Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a…View Resource Rheumatic Associated Macrophage Activation SyndromeJanuary 1, 1970Macrophage Activation Syndrome (MAS) is a hyperinflammatory condition that has a significant mortality risk and…View Resource Still’s Disease FAQsJanuary 1, 1970What is the classic ‘triad’ of Still’s disease? Does it affect males and females…View Resource ACR 2022 Appraisal, Praise & Critique (11.18.2022)January 1, 1970It was great to be back at an ACR annual meeting, this one in…View Resource Here at Last: Treatment Options for VEXASJanuary 1, 1970We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…View Resource ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory SyndromesJanuary 1, 1970Editor’s note: This article originally appeared March 12, 2024, and is being shared again…View Resource ERA, APPs, & Alpha GAL (3.21.2025)January 1, 1970Dr. Jack Cush reviews the news and journal reports from this past week on…View Resource ←123456789…1011121314
Rheumatic Associated Macrophage Activation SyndromeJanuary 1, 1970Macrophage Activation Syndrome (MAS) is a hyperinflammatory condition that has a significant mortality risk and…View Resource Still’s Disease FAQsJanuary 1, 1970What is the classic ‘triad’ of Still’s disease? Does it affect males and females…View Resource ACR 2022 Appraisal, Praise & Critique (11.18.2022)January 1, 1970It was great to be back at an ACR annual meeting, this one in…View Resource Here at Last: Treatment Options for VEXASJanuary 1, 1970We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…View Resource ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory SyndromesJanuary 1, 1970Editor’s note: This article originally appeared March 12, 2024, and is being shared again…View Resource ERA, APPs, & Alpha GAL (3.21.2025)January 1, 1970Dr. Jack Cush reviews the news and journal reports from this past week on…View Resource ←123456789…1011121314
Still’s Disease FAQsJanuary 1, 1970What is the classic ‘triad’ of Still’s disease? Does it affect males and females…View Resource ACR 2022 Appraisal, Praise & Critique (11.18.2022)January 1, 1970It was great to be back at an ACR annual meeting, this one in…View Resource Here at Last: Treatment Options for VEXASJanuary 1, 1970We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…View Resource ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory SyndromesJanuary 1, 1970Editor’s note: This article originally appeared March 12, 2024, and is being shared again…View Resource ERA, APPs, & Alpha GAL (3.21.2025)January 1, 1970Dr. Jack Cush reviews the news and journal reports from this past week on…View Resource ←123456789…1011121314
ACR 2022 Appraisal, Praise & Critique (11.18.2022)January 1, 1970It was great to be back at an ACR annual meeting, this one in…View Resource Here at Last: Treatment Options for VEXASJanuary 1, 1970We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…View Resource ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory SyndromesJanuary 1, 1970Editor’s note: This article originally appeared March 12, 2024, and is being shared again…View Resource ERA, APPs, & Alpha GAL (3.21.2025)January 1, 1970Dr. Jack Cush reviews the news and journal reports from this past week on…View Resource ←123456789…1011121314
Here at Last: Treatment Options for VEXASJanuary 1, 1970We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…View Resource ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory SyndromesJanuary 1, 1970Editor’s note: This article originally appeared March 12, 2024, and is being shared again…View Resource ERA, APPs, & Alpha GAL (3.21.2025)January 1, 1970Dr. Jack Cush reviews the news and journal reports from this past week on…View Resource ←123456789…1011121314
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory SyndromesJanuary 1, 1970Editor’s note: This article originally appeared March 12, 2024, and is being shared again…View Resource ERA, APPs, & Alpha GAL (3.21.2025)January 1, 1970Dr. Jack Cush reviews the news and journal reports from this past week on…View Resource ←123456789…1011121314
ERA, APPs, & Alpha GAL (3.21.2025)January 1, 1970Dr. Jack Cush reviews the news and journal reports from this past week on…View Resource